West Pharmaceutical Services (NYSE:WST) Hits New 52-Week High – Should You Buy?

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $323.29 and last traded at $323.4840, with a volume of 710743 shares changing hands. The stock had previously closed at $312.55.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on WST. Morgan Stanley set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, April 27th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. Finally, UBS Group reissued a “buy” rating and set a $340.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $322.89.

West Pharmaceutical Services Stock Performance

The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average price is $259.93 and its two-hundred day moving average price is $263.91. The firm has a market capitalization of $22.78 billion, a PE ratio of 43.11, a PEG ratio of 2.59 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s revenue was up 21.0% on a year-over-year basis. During the same period last year, the company posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 8.61 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is presently 11.76%.

West Pharmaceutical Services announced that its board has approved a stock buyback program on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

Institutional Trading of West Pharmaceutical Services

Hedge funds and other institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at $272,041,000. Generation Investment Management LLP lifted its holdings in shares of West Pharmaceutical Services by 60.0% during the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after acquiring an additional 585,855 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of West Pharmaceutical Services by 22.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock valued at $726,895,000 after acquiring an additional 503,601 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of West Pharmaceutical Services by 67.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after acquiring an additional 473,547 shares in the last quarter. Finally, Steadfast Capital Management LP acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter valued at $123,667,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.